This article first appeared on GuruFocus .
-
Cash and Cash Equivalents:$34.0 million as of June 30, 2026, compared to $13.2 million as of December 31, 2025.
-
R&D Expenses:$4.6 million for Q2 2026, up from $2.4 million in Q2 2025.
-
G&A Expenses:$2.6 million for Q2 2026, down from $3.6 million in Q2 2025.
-
Net Loss:$6.9 million, or $0.57 per share, for Q2 2026, compared to $5.4 million, or $3.39 per share, in Q2 2025.
-
Financing:Completed oversubscribed financing in May with $35 million gross upfront (approximately $31.7 million net) and up to $105 million tied to future milestones.
Release Date: August 13, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Cellectar Biosciences Inc ( NASDAQ:CLRB ) reported strong clinical data from the CLOVER WaM study, with a 79.2% major response rate and 87.5% overall response rate in patients treated immediately after BTKi therapy, and a median duration of response of 16 months.
-
The company completed an oversubscribed financing in May, securing up to $140 million in potential capital, including $35 million upfront, to support its regulatory and clinical programs.
-
Cellectar Biosciences Inc ( NASDAQ:CLRB ) has initiated site activation for its confirmatory Phase 3 study of iopofosine I 131 in Waldenstrom macroglobulinemia, with first patient dosing expected late 2026 or early 2027.
-
The company is on track to submit a New Drug Application (NDA) for accelerated approval of iopofosine I 131 in mid-2027, with a potential six-month FDA review due to Breakthrough Therapy designation.
-
Cellectar Biosciences Inc ( NASDAQ:CLRB ) is advancing its versatile PDC platform, with CLR 125 (Auger-emitting) and CLR 225 (alpha-emitting) programs, and has dosed the first patients in the Phase 1b trial for triple-negative breast cancer.
-
The company has a robust commercial supply chain, with the ability to produce up to 100 patients' worth of finished product per week, and has multi-sourced key components like actinium-225 to mitigate supply risks.
Negative Points
-
Cellectar Biosciences Inc ( NASDAQ:CLRB ) reported a net loss of $6.9 million for Q2 2026, with R&D expenses nearly doubling year-over-year to $4.6 million due to increased clinical activity.
-
The company's cash position of $34.0 million is relatively low, and it relies on future milestone-based warrant exercises (up to $105 million) to fund operations, which are contingent on achieving specific clinical and regulatory milestones.
-
The confirmatory Phase 3 study initiation is still in early stages, with first patient dosing not expected until late 2026 or early 2027, and the FDA submission is dependent on having 10-20 sites open and a few patients enrolled, which may be challenging to achieve.
-
The company faces uncertainty regarding the FDA's definition of 'ongoing' for the confirmatory study, which could impact the timing of the accelerated approval submission and potential approval.
-
Cellectar Biosciences Inc ( NASDAQ:CLRB ) has not yet provided specific data updates for CLR 125, and initial dosimetry, safety, and efficacy data are not expected until late 2026 or early 2027, leaving a gap in pipeline visibility.
-
The company's commercial strategy for iopofosine is still undecided, with options including self-commercialization or partnering, which could lead to delays or additional costs in the launch process.
Q & A Highlights
Q: What are the gating steps to first patient enrollment in the Phase 3 WM confirmatory study, and what specifically triggers the FDA submission for accelerated approval? A: Jarrod Longcor, COO, detailed the extensive site activation process, including CRO contracting, site identification, feasibility questionnaires, qualification for radiopharmaceutical handling, IRB approvals (central for community sites, local for academic centers), and training. He clarified that the FDA requires the study to be "initiated" at submission and "ongoing" at regulatory action. The company's interpretation is to have 10-20 sites open and a couple of patients enrolled at submission, with 5% or more enrolled by the time of regulatory action, targeting a March-April 2027 submission.
Q: Can you provide more granularity on the timeline for initial data from the CLR 125 Phase 1b trial in Triple Negative Breast Cancer? A: Jarrod Longcor, COO, stated that while he would remain vague on specific dosimetry trends, the company expects to provide data later this year. He identified the San Antonio Breast Cancer Conference as a potential venue for presenting initial dosimetry, safety, and efficacy data, noting that tumor uptake and biodistribution are in line with predictions based on the targeting ligand.
Q: Are you manufacturing commercial supply for iopofosine I 131, and how quickly could you launch after receiving accelerated approval? A: Jarrod Longcor, COO, confirmed the company produces the targeting ligand at commercial scale with over five years of stability data, while the finished product is produced just-in-time. He noted the commercial infrastructure is built out and can scale to approximately 100 patients per week. For launch, he indicated a 12-month minimum to fully "lock and load" for commercial execution, but the targeted WM market (15 states control 80% of patients) allows for a rapid, cost-effective launch, with options including self-commercialization or partnering.
Q: What is your sense of the availability of actinium-225 now versus a year ago, and how does that impact your CLR 225 program? A: Jarrod Longcor, COO, noted that while supply chain concerns persist, the landscape has improved with new suppliers like SpectronRx, ITM, Eckert & Ziegler, and Northstar coming online. He emphasized the company's strategy of multi-sourcing every component, including having ready supply agreements with four parties for actinium, to ensure access for both near-term and long-term program needs.
Q: What were the key financial results for the second quarter of 2026, and how does the recent financing support the company's strategy? A: Chad Kolean, CFO, reported cash and cash equivalents of $34.0 million as of June 30, 2026, up from $13.2 million at year-end 2025, reflecting the $35 million gross upfront from the May financing. R&D expenses increased to $4.6 million (from $2.4 million) due to CLR 125 study activity and confirmatory study initiation, while G&A decreased to $2.6 million (from $3.6 million). Net loss was $6.9 million, or $0.57 per share. The financing includes up to $105 million in milestone-based warrants tied to study initiation, NDA acceptance, and FDA approval.
Q: What were the key clinical data updates presented at ASCO 2026 and in the full 12-month follow-up from the CLOVER WaM study? A: Jim Caruso, CEO, highlighted data from patients treated immediately following BTKi therapy, showing a 79.2% major response rate, 87.5% overall response rate, and 100% clinical benefit rate with a median duration of response of 16 months. Jarrod Longcor, COO, added that the full 12-month follow-up data showed a median durability of 17.8 months, with approximately 62% of patients achieving a major response and VGPR/CR rates increasing to 14.5%.
Q: What is the status of the site activation for the Phase 3 confirmatory study, and what is the expected timeline for first patient dosing? A: Jim Caruso, CEO, stated that site activation activities have been initiated, with strong interest from both academic centers and community oncology networks. Jarrod Longcor, COO, confirmed the company is on track to open first sites in the coming months, with potential first patient dosing late this year or early next year, which is viewed as a significant upcoming catalyst.
Q: How does the PDC platform support the broader pipeline beyond iopofosine, and what are the next steps for CLR 125 and CLR 225? A: Jarrod Longcor, COO, explained that the PDC platform is highly versatile, capable of delivering beta, Auger, and alpha-emitting radiotherapeutics. CLR 125 (Auger-emitting) has enrolled and dosed first patients in a Phase 1b trial for Triple Negative Breast Cancer, with initial data expected late 2026 or early 2027. CLR 225 (alpha-emitting) is in preclinical development. The company plans to host an educational webinar on August 18 to discuss the platform's scientific foundation and future opportunities.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
